Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [177Lu-[DOTA0, Tyr3]-octreotate

EJNMMI Research

Table 3 Absorbed dose per administered activity (AD/A admin; in mGy/MBq) to the liver, kidneys, spleen, and red marrow after cycle 1 and cycle 2. The AD/A admin presented in the table were calculated with personalized organ masses

Patients	Absorbed dose per administered activity (mGy/MBq)
	Liver		Kidneys		Spleen		Red marrow
	Cycle 1	Cycle 2	Cycle 1	Cycle 2	Cycle 1	Cycle 2	Cycle 1	Cycle 2
1	NA	0.29	NA	0.42	NA	0.89	NA	0.07
2	1.92	†	0.28	†	0.59	†	0.07	†
3	0.17	0.17	0.47	0.49	0.88	0.59	NA	NA
4	0.46	0.32	0.39	0.46	0.42	0.58	0.02	0.03
5	0.28	0.23	0.34	0.35	0.49	0.48	0.04	0.01
6	0.15	0.19	0.27	0.36	0.45	0.76	0.03	0.02
7	2.26	1.22	0.40	0.49	0.55	0.70	0.03	0.02
8	0.13	0.12	0.44	0.54	0.52	0.55	0.04	0.04
9	0.33	0.31	0.34	0.32	0.58	0.56	0.07	0.05
10	0.55	0.59	0.45	0.50	0.57	0.75	0.03	0.04
11	0.64	1.03	0.50	0.91	0.70	0.76	NA	NA
12	0.22	0.22	0.35	0.37	0.56	0.51	0.06	0.09